How much cash does Pelthos Therapeutics Inc. generate?

Pelthos Therapeutics Inc. (PTHS) generated -$35.1M in operating cash flow over the trailing twelve months.

What is Pelthos Therapeutics Inc.'s free cash flow?

After $194.0K of capital expenditures, Pelthos Therapeutics Inc.'s free cash flow was -$16.8M over the trailing twelve months.

Where does Pelthos Therapeutics Inc.'s cash flow data come from?

Every line is extracted from Pelthos Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Pelthos Therapeutics Inc. PTHS Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$51.59M-601%	-$43.32M-445%	-$23.58M-134%	-$9.04M+7.7%	-$7.36M+18.0%
Depreciation and amortization	——	——	——	——	$0—
Stock-based compensation	$6.88M+245%	$5.46M+204%	$4.19M+103%	$1.95M+3.3%	$1.99M+13.6%
Change in accounts receivable	——	——	——	——	$0—
Change in inventories	——	——	——	——	$0—
Change in accounts payable	——	——	$4.65M+357%	$5.76M+1,532%	$1.8M+32.9%
Change in accrued liabilities	$4.26M+3,349%	$6.16M+2,278%	$2.69M+1,453%	$23.15K+126%	-$130.98K-187%
Change in deferred revenue	——	——	——	——	$0—
Change in prepaid expenses	——	——	——	——	——
Amortization of intangible assets	——	——	——	——	$0—
Non-cash operating lease expense	——	——	——	——	$0—
Change in operating lease liabilities	——	——	——	——	$0—
Debt issuance costs and discount amortization	$360K+99.6%	$259K-62.6%	$335K-54.6%	$345.26K-53.6%	$180.37K-76.3%
Net cash from operating activities	-$35.08M-692%	-$22.59M-290%	-$17.01M-210%	-$1.93M+65.3%	-$4.43M-58.3%
Capital expenditures	——	——	——	——	$0—
Acquisitions, net of cash acquired	——	$2.76M—	$2.07M—	$1.38M—	$690.25K—
Net cash from investing activities	——	——	——	——	$0—
Proceeds from issuance of debt	$443K-32.1%	$693K+29.3%	$827K+96.0%	$893K+136%	$652K—
Payment of debt issuance costs	——	——	——	——	——
Net cash from financing activities	$72.61M—	$45.34M—	——	——	——
Net increase (decrease) in cash	$32.1M—	$17.51M—	——	——	——
Interest paid	$710K—	$19K—	$19K—	$18.75K—	$0—
Income taxes paid	——	——	——	——	$0—
Non-cash interest expense	——	——	——	——	$0—
Amortization Of Debt Discount Premium	$360K+99.6%	$259K-62.6%	$335K-54.6%	$345.26K-53.6%	$180.37K-76.3%
Amortization of capitalized software and acquired intangible assets	$2.59M—	$1.56M—	$679K—	$0—	$0—
Contingent consideration	——	——	——	——	$0—
Change in fair value of convertible debt	——	——	——	——	$0—
Depreciation	——	——	——	——	$0—
Gain (Loss) from Litigation Settlement	——	$0-100%	$90.75K—	$181.5K—	$272.25K—
Increase (Decrease) in Deferred Income Taxes	——	$7.39M—	$5.54M—	$3.69M—	$1.85M—
Operating lease liabilities	——	——	——	——	$0—
Increase (Decrease) In Operating Lease Right-Of-Use Assets	——	——	——	——	$0—
Increase (Decrease) in Prepaid Expense	——	——	——	——	——
Operating lease right-of-use asset amortization	——	——	——	——	$0—
Payments For Recission Of Common Stock	——	$0-100%	$23K—	$46K—	$69K—
Payments Of Debt Issuance Costs	——	——	——	——	——
Shares issued for cash under equity line of credit	——	$0-100%	$20.75K—	$41.5K—	$62.25K—
Repayments of Debt	——	$845K+293%	$687.5K—	$530K—	$372.5K—
Value of common stock issued to settle convertible senior notes	——	$737K-45.9%	$893.5K—	$1.05M—	$1.21M—
Debt discount from common stock issued for extension of bridge loan	——	$0-100%	$112K—	$224K—	$336K—
Increase Decrease In Contract With Customer Liability	——	——	——	——	$0—
Increase Decrease In Operating Lease Liability	——	——	——	——	$0—
Offering costs recorded to debt discount	——	——	——	——	——
Payment-in-kind on convertible debt	——	——	——	——	——
Proceeds from secured term loan	——	——	——	——	——
Royalty obligation extinguishment	——	$369K—	$276.75K—	$184.5K—	$92.25K—
Shares issued for payment of accrued interest	——	$0-100%	$750—	$1.5K—	$2.25K—
Shares issued for payment of principal on loan payable	——	$0-100%	$6K—	$12K—	$18K—
Issuance of common stock for the acquisition of Ansys	——	$53K+657%	$41.5K—	$30K—	$18.5K—
Transfer of liabilities to Chromocell Corporation for Series C Preferred Stock	——	$0-100%	$538.25K—	$1.08M—	$1.61M—
Warrants issued for venture loan and security agreement	——	——	——	——	——
Income Taxes Paid, Net	——	——	——	——	$0—
Free cash flow	——	——	——	——	-$4.98M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Pelthos Therapeutics Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Pelthos Therapeutics Inc. generate?: Pelthos Therapeutics Inc. (PTHS) generated -$35.1M in operating cash flow over the trailing twelve months.
What is Pelthos Therapeutics Inc.'s free cash flow?: After $194.0K of capital expenditures, Pelthos Therapeutics Inc.'s free cash flow was -$16.8M over the trailing twelve months.
Where does Pelthos Therapeutics Inc.'s cash flow data come from?: Every line is extracted from Pelthos Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.